CJC-1295 with DAC

Overview

CJC-1295 is a synthetic 29-amino-acid analog of GHRH (growth hormone-releasing hormone) that was engineered to solve one specific problem: natural GHRH has a half-life of minutes, which makes it practically useless as a therapeutic. CJC-1295 fixes that by attaching a reactive maleimidopropionic acid group — marketed as the Drug Affinity Complex, or DAC — that covalently bonds to circulating albumin in your bloodstream. Once bound, a single dose can stimulate measurable GH release for more than six days.[1]

That's not a minor pharmacological tweak. That's the difference between a compound you'd need to inject multiple times daily and one you could theoretically dose once or twice a week. The 2006 trial published in the Journal of Clinical Endocrinology and Metabolism demonstrated this in healthy adults, which is still the primary human clinical data supporting the compound's mechanism.[1]

CJC-1295 has no FDA approval and no ongoing Phase 3 trials. In the US, it exists in a research-only gray zone — which means if you've seen it offered by a telehealth clinic or purchased it online, you're operating outside FDA-approved medicine. That reality shapes everything about how to evaluate this compound.

Mechanism of Action

GHRH receptor agonism + albumin binding via DAC group

Your pituitary gland releases growth hormone in pulses, triggered largely by GHRH — a 44-amino-acid peptide produced in the hypothalamus. GHRH binds to specific receptors on somatotroph cells in the pituitary, which then release stored GH into circulation. GH travels to the liver and other tissues, where it stimulates production of IGF-1 (insulin-like growth factor 1), which handles most of GH's downstream effects: protein synthesis, fat metabolism, tissue repair, and bone density maintenance.

CJC-1295 is a truncated, modified version of GHRH. The first 29 amino acids of native GHRH contain the full receptor-binding activity — the remaining 15 amino acids are essentially a spacer that doesn't contribute to potency.[1] So CJC-1295 at 29 amino acids retains the full agonist activity of the 44-amino-acid parent molecule. The modifications to the amino acid sequence also make it more resistant to enzymatic degradation than native GHRH, which extends its intrinsic half-life even before the DAC group is factored in.

Once injected subcutaneously, CJC-1295 absorbs into the bloodstream, binds albumin via the DAC group, and begins activating GHRH receptors on the pituitary. The pituitary responds by releasing GH in amplified pulses over the following days. Elevated circulating GH then drives hepatic IGF-1 production. In the 2006 trial, mean IGF-1 levels increased 1.5–3 fold above baseline and remained elevated for 9–11 days after a single injection.[1]

IGF-1 is the number most practitioners and patients actually track, because it's measurable with a standard blood test and reflects the cumulative anabolic signal from GH over time. GH itself is harder to measure meaningfully due to its pulsatile release pattern.

What the Evidence Shows

The foundational human data comes from a single study: Teichman et al., published in the Journal of Clinical Endocrinology and Metabolism in 2006.[1] This was a dose-escalation study in healthy adults testing single subcutaneous doses of 30, 60, and 120 mcg/kg. All three doses produced a 2–3 fold increase in mean GH levels that persisted for more than 6 days, and IGF-1 levels remained elevated for 9–11 days. The study also tested multiple doses over 28 days and found that GH and IGF-1 elevations were maintained without tachyphylaxis — meaning the pituitary didn't appear to downregulate its response over that short observation window.[1]

That's a meaningful pharmacokinetic result. It confirms the DAC mechanism works as intended in humans, and it establishes that the compound reaches its target and produces the expected hormonal response.

What the 2006 study did not do: test any clinical endpoint. No body composition data. No bone density measurements. No cardiovascular markers. No quality-of-life outcomes. The study was designed to characterize pharmacokinetics and safety signals, not to demonstrate that CJC-1295 actually does anything useful for patients beyond raising a number on a lab report.

Beyond that trial, the human evidence base is sparse. A 2016 netnography study examined online communities of women using CJC-1295 for muscle enhancement, fat loss, and skin quality — documenting self-reported use patterns and motivations, but not clinical outcomes.[4] Two additional published studies from 2019 focused entirely on detection methodology for anti-doping purposes in equine plasma, confirming the compound's presence in illicit performance enhancement contexts but contributing nothing to clinical efficacy data.[2][5]

Side Effects
The side effect profile of CJC-1295 reflects what you'd expect from sustained GH and IGF-1 elevation. The 2006 trial reported that most adverse events were mild and transient.[1] Specific incidence percentages from that trial should be interpreted cautiously — it was a small pharmacokinetic study, not a powered safety trial.

If you develop persistent numbness, significant edema, or any signs of blood sugar dysregulation while using CJC-1295, those are specific reasons to stop and consult a provider — not just generic reasons to "monitor for side effects."